logo
Plus   Neg
Share
Email

Top 5 Stocks That Gained Over 25% (TCMD, MBOT, PLXP...)

pharmaup-jan08-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Microbot Medical Inc. (MBOT)

Microbot Medical is a medical device company specializing in the design and development of transformational micro-robotic medical technologies.

Gained 46.83% to close Tuesday's (Jan.8) trading at $2.77.

News: No news

Near-term Catalysts:

-- Results of an independent in-vitro study of the Company's Self-Cleaning Shunt, or SCS, for treating Hydrocephalus, also known as "water in the brain", to be announced this year.
-- Completion of the pivotal pre-clinical study of the SCS being performed at Washington University in St. Louis School of Medicine and Wayne State University in the third quarter of 2019.
-- Finalization of the FDA regulatory pre-submission request for the SCS in the second half of 2019.

2. PLx Pharma Inc. (PLXP)

Gained 35.11% to close Tuesday's trading at $3.04.

PLx is a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore 325 mg and Vazalore 81 mg (referred to together as "Vazalore").

Vazalore 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients. The Company is focused on manufacturing, scale-up and label finalization for Vazalore 325 mg aspirin dosage form and preparing an sNDA for Vazalore 81 mg maintenance dose form.

News: No news

Anticipated milestone:

The launch of Vazalore 325 mg and Vazalore 81 mg is planned for mid-2020.

3. vTv Therapeutics Inc. (VTVT)

Gained 31.65% to close Tuesday's trading at $3.12.

News: No news

Clinical Trials & Near-term Catalysts:

The lead drug candidate is Azeliragon. A phase III study, which evaluated Azeliragon in patients with mild Alzheimer's disease failed to meet the primary endpoints. However, data suggests potential efficacy at lower drug concentrations. Moreover, a subgroup analysis from the STEADFAST trial indicated the potential benefit of treatment with Azeliragon for patients with Type 2 Diabetes and Alzheimer's disease.
The Company is working with the FDA and EMA to determine regulatory approval pathways.

Next in the pipeline is TTP399. The phase II portion of the Simplici-T1 study, which is a phase I/II study evaluating TTP399 as an insulin-adjunctive therapy for Type 1 Diabetes is underway, with interim analysis expected in early 2019.

4. Axsome Therapeutics Inc. (AXSM)

Gained 29.26% to close Tuesday's trading at $8.88.

News: This is the second straight day of double-digit gain since the Company reported encouraging results from its phase II study of AXS-05 in major depressive disorder, dubbed ASCEND.

The ASCEND study results were reported on January 7, which sent the stock up more than 161% to $6.87 that day. The stock has gained over 230% in two days.

5. Tactile Systems Technology Inc. (TCMD)

Tactile Systems Technology is a medical technology company focused on developing medical devices for the treatment of chronic diseases at home.

Gained 29.26% to close Tuesday's trading at $8.88.

News: The Company reported preliminary revenue results for the full year and fourth quarter ended December 31, 2018, well above analysts' expectations.

Fourth quarter total revenue is expected to be in the range of $45.5 million to $46.0 million, representing growth of approximately 30% to 32% year-over-year. Analysts polled by Thomson Reuters are expecting revenue of $38.86 million.

Full-year 2018 total revenue is expected to be in the range of $142.8 million to $143.3 million, representing growth of approximately 31% year-over-year. Analysts are expecting revenue of $137.72 million.

The Company intends to report its full year and fourth quarter 2018 financial results in February.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT